Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS

Liliana E. Lucca, PhD,* Benjamin A. Lerner, MD,* Calvin Park, BA, Danielle DeBartolo, MS, Brian Harnett, BA, Varun P. Kumar, MD, Gerald Ponath, PhD, Khadir Raddassi, PhD, Anita Huttner, MD, David A. Hafler, MD, and David Pitt, MD

Neurol Neuroimmunol Neuroinflamm 2020;7:e712. doi:10.1212/NXI.0000000000000712

Correspondence
Dr. Pitt
david.pitt@yale.edu

Abstract

Objective
To identify coinhibitory immune pathways important in the brain, we hypothesized that comparison of T cells in lesions from patients with MS with tumor-infiltrating T cells (TILs) from patients with glioblastoma multiforme may reveal novel targets for immunotherapy.

Methods
We collected fresh surgical resections and matched blood from patients with glioblastoma, blood and unmatched postmortem CNS tissue from patients with MS, and blood from healthy donors. The expression of TIGIT, CD226, and their shared ligand CD155 as well as PD-1 and PDL1 was assessed by both immunohistochemistry and flow cytometry.

Results
We found that TIGIT was highly expressed on glioblastoma-infiltrating T cells, but was near-absent from MS lesions. Conversely, lymphocytic expression of PD-1/PD-L1 was comparable between the 2 diseases. Moreover, TIGIT was significantly upregulated in circulating lymphocytes of patients with glioblastoma compared with healthy controls, suggesting recirculation of TILs. Expression of CD226 was also increased in glioblastoma, but this costimulatory receptor was expressed alongside TIGIT in the majority of tumor-infiltrating T cells, suggesting functional counteraction.

Conclusions
The opposite patterns of TIGIT expression in the CNS between MS and glioblastoma reflect the divergent features of the immune response in these 2 CNS diseases. These data raise the possibility that anti-TIGIT therapy may be beneficial for patients with glioblastoma.

*These authors contributed equally to this work.

From the Departments of Neurology (L.E.L., B.A.L., C.P., D.D., B.H., V.P.K., G.P., K.R., D.A.H., D.P.); Immunobiology (L.E.L., B.A.L., B.H., K.R., D.A.H.); and Pathology (A.H.), Yale School of Medicine, New Haven, CT.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the NIH.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Immune checkpoint receptors are a family of coinhibitory receptors that modulate T-cell activation. The interactions between coinhibitory receptors on tumor-infiltrating T cells and their ligands expressed by tumor cells is believed to contribute to the failure of the immune system to reject tumors.1,2 Therapeutic blockade of this interaction has yielded dramatic results in the therapy of multiple cancer types. To date, this has led to FDA approval of 6 immune checkpoint inhibitors that target cytotoxic T-lymphocyte-associated protein 4 (CTLA-4, ipilimumab) and programmed cell death protein 1 and its ligand (PD-1, pembrolizumab and nivolumab; PD-L1, atezolizumab, avelumab, and durvalumab).3–8

To identify coinhibitory pathways that may be important in the CNS, we hypothesized that comparison of T cells in lesions from patients with the autoimmune disease MS with tumor-infiltrating T cells (TILs) of tumor from patients with glioblastoma multiforme (GBM) may reveal novel targets for immunotherapy in patients with CNS tumors. This approach was suggested by the role in coinhibitory and costimulatory pathways in T-cell regulation in preventing activation of autoreactive T cells and by the high incidence of autoimmune manifestations associated with therapeutic blockade of checkpoint inhibitors.9–11 We focused on the T-cell immunoreceptor with Ig and ITIM domains (TIGIT) axis, a recently discovered coinhibitory receptor expressed by activated T cells and natural killer cells, and on PD-1/PDL-1.12,13 TIGIT shapes T-cell function directly by repressing proinflammatory Th1 and Th17 but not Th2 responses14 and indirectly by enhancing dendritic cell production of IL-10.12 TIGIT also prevents costimulatory signaling through CD226 by competing for the same ligand, CD155, and by disrupting CD226 homodimerization.15 Moreover, TIGIT is a marker of highly suppressive regulatory T cells (Tregs) and directly promotes Treg function in environments of Th1 inflammation.16,17 TIGIT has been investigated as a novel candidate target of cancer immunotherapy. Indeed, increased TIGIT has been demonstrated on tumor-infiltrating lymphocytes in a number of cancers including non–small-cell lung cancer and melanoma.15,18 Moreover, TIGIT blockade in animal models and in CD4 and CD8 T cells isolated from human tumors showed reactivation of antitumor immune responses.15,19,20 However, TIGIT blockade also has the potential for inducing autoimmune disease, as expression of the competing costimulatory receptor, CD226, is increased on peripheral T cells of patients with rheumatoid arthritis and lupus.21 In addition, a coding variant in the CD226 gene is associated with multiple autoimmune diseases, including MS and rheumatoid arthritis.22 Finally, TIGIT-deficient mice displayed increased susceptibility to developing experimental autoimmune encephalomyelitis (EAE), an animal model of MS,19,23 whereas treatment with a CD226-blocking monoclonal antibody delayed onset and reduced severity of EAE.24

Here, we examined expression of TIGIT, CD226, their shared ligand CD155, and of PD-1 and its ligand PD-L1 in 2 prototypic neoplastic and autoimmune CNS diseases, glioblastoma and MS. Our data show that TIGIT+ T cells were highly prevalent in glioblastoma infiltrates but not in MS lesions, whereas the frequency of PD-1+ and PD-L1+ lymphocytes was comparable in the 2 conditions. Our findings highlight specific differences in immune checkpoint expression between glioblastoma and MS and provide a strong rationale for developing immunotherapy against TIGIT for glioblastoma.

### Methods

#### Tissue and blood samples

Immunohistochemistry was performed on formalin-fixed tissue from 6 patients with MS (obtained through autopsy) and 6 patients with glioblastoma (resection/biopsy). Flow cytometry was performed on blood from 5 healthy volunteers and on freshly resected glioblastoma tissue and matched blood from 7 patients (1 tumor did not yield enough T cells for analysis, table).

#### Standard protocol approvals, registrations, and patient consents

All samples were collected according to institutional review board–approved protocols conformed to the principles of the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report; all patients and healthy volunteers gave informed consent.

#### Immunohistochemistry

Formalin-fixed paraffin-embedded sections were prepared for immunohistochemistry as described elsewhere.10 Serial sections were stained with primary antibodies against CD68 (Cell Signaling #76437, 1:500), MBP (Millipore Sigma MAB386, 1:500), CD3 (Dako A 40452, 1:200), TIGIT (Santa Cruz sc-103349, 1:800), CD226 (Novus Biologicals NBP1-85001, 1:50), CD155 (Bioss Inc. bs-2525R, 1:750), CD226 (Novus Biologicals MAB386, 1:500), CD3 (Dako A 40452, 1:200), TIGIT (Santa Cruz sc-103349, 1:800), CD226 (Novus Biologicals NBP1-85001, 1:50), CD155 (Bioss Inc. bs-2525R, 1:750), PD-1 (Acris Antibodies AP23805PU-M, 1:100), and PD-L1 (Spring Bioscience M4420, 1:50) and processed with the appropriate biotinylated secondary antibodies (Vector Laboratories, Burlingame CA) and avidin-biotin staining kit with dianinobenzidine as chromogen. Sections were counterstained with hematoxylin. Images were taken on a Leica DM5000 B microscope with Leica color camera DFC310 Fx Leica Application Suite (version 4.2.0) imaging software. An overview picture of a chronic active MS lesion (MS case 4) is shown in supplementary figure 1, links.lww.com/NXI/A232.

---

**Glossary**

EAE = experimental autoimmune encephalomyelitis; GBM = glioblastoma multiforme; ROI = regions of interest.
### Table Clinical data of patients with MS and GBM

#### 1. Immunohistochemistry

**MS cases (tissue; immunohistochemistry)**

| Case | Age | Sex  | PMI | Disease course/duration | Lesion types | Lesions examined |
|------|-----|------|-----|-------------------------|--------------|------------------|
| MS 1 | 68  | Male | 12 h| Asymptomatic\(^a\); unknown | Chronic active | 1                |
| MS 2 | 31  | Female | 3 h | RRMS; 8 y                | Chronic active | 5                |
| MS 3 | 39  | Male | 8 h | RRMS; 15 y               | Chronic active | 2                |
| MS 4 | 27  | Female | 4 h | RRMS; 10 y               | Chronic active | 1                |
| MS 5 | 32  | Female | 8 h | RRMS; 6 y                | Chronic active | 3                |
| MS 6 | 62  | Female | NA\(^b\) | RRMS; 7 wk | Acute       | 1                |

#### 2. Flow cytometry and in vitro experiments

**Patients with GBM (tissue; blood); flow cytometry**

| Case | Age | Sex  | PMI  | Tumor location | IDH1 status/MGMT methylation |
|------|-----|------|------|----------------|-------------------------------|
| GBM 1| 79  | Female | NA\(^b\) | Right parietal | Unmethylated                  |
| GBM 2| 65  | Male  | NA\(^b\) | Left temporoparietal | Partially methylated         |
| GBM 3| 40  | Male  | NA\(^b\) | Right parietal | Unmethylated                  |
| GBM 4| 66  | Female | NA\(^b\) | Left posteriortemporal | ND                           |
| GBM 5| 64  | Male  | NA\(^b\) | Left parietal | ND                            |
| GBM 6| 43  | Male  | NA\(^b\) | Right temporal | ND                            |

**Patients with GBM (blood); in vitro experiment**

| Case | Age | Sex  | PMI  | Tumor location | IDH1 status/MGMT methylation |
|------|-----|------|------|----------------|-------------------------------|
| GBM 8| 64  | Male  | NA\(^b\) | Left occipital | Negative/partially methylated |
| GBM 9| 69  | Male  | NA\(^b\) | Left parietal | Negative/partially methylated |
| GBM 10| 40  | Female | NA\(^b\) | Left cerebellar | Negative/methylated         |
| GBM 11| 66  | Male  | NA   | Left temporal | Negative/methylated          |
| GBM 12| 56  | Male  | NA\(^b\) | Right parietal | Negative/unmethylated        |
| GBM 13| 78  | Female | NA\(^b\) | Right occipital | Negative/methylated         |
| GBM 14| 64  | Male  | NA\(^b\) | Left frontal | Negative/unmethylated        |
| GBM 15| 42  | Male  | NA\(^b\) | Left frontal | Negative/unmethylated        |
| GBM 16| 63  | Female | NA\(^b\) | Right parietal | Negative/partially methylated |
| GBM 17| 76  | Female | NA\(^b\) | Right temporal-parietal | Negative/methylated |
| GBM 18| 78  | Male  | NA\(^b\) | Left temporal | Negative/methylated          |
| GBM 19| 70  | Male  | NA\(^b\) | Right temporal | Negative/unmethylated        |
| GBM 20| 77  | Female | NA\(^b\) | Left occipital | Negative/partially methylated |

Abbreviation: GBM = glioblastoma multiforme.
All GBM cases were negative for IDH mutations.
\(^a\) Discovered at autopsy.
\(^b\) Biopsy.
Cellular quantification
We identified multiple areas of lymphocytic infiltration both in the perivascular space and the parenchyma in MS lesion and GBM tissue sections that were immunolabeled with antibody against CD3. In GBM tissue, this included infiltrates in vital tumor tissue and in areas surrounding tissue necrosis. In MS tissue, the vast majority of infiltrates were present in perivascular spaces. In these regions of interest (ROIs), CD3+ cells were quantified manually. The same ROIs were selected in adjacent sections immunolabeled with antibodies against TIGIT, CD226, CD155, PD-1, or PDL-1. Immunolabeled cells with a lymphocytic morphology were manually quantified. We distinguished cells present in the perivascular space, i.e., within the borders of the glia limitans, and in the parenchyma. All cells were counted independently by 3 investigators (D.D., V.P.K., and G.P.), and the counts were averaged. The number of TIGIT+, CD226+, CD155+, PD-1−, or PDL-1+ cells was correlated with the number of CD3+ lymphocytes found in each ROI.

Flow cytometry
Peripheral blood mononuclear cells were isolated from whole blood by Ficoll-Paque gradient centrifugation. Freshly resected tumor specimens were manually disrupted followed by digestion with collagenase IV (2.5 mg/mL) and DNase I (0.2 mg/mL) (Worthington Biochemical Corporation) for 1 hour. Tumor homogenates were separated on discontinuous 70%–30% Percoll (Sigma-Aldrich) gradients. Flow cytometric analysis was performed with antibodies targeting CD4 (BD Biosciences clone RPA-T4, V450 conjugated), CD226 (eBioscience clone DX11, V450 conjugated), CD8 (BD Biosciences clone RPA-T8, V500 conjugated), TIGIT (eBioscience clone MBSA43, PerCP-eFluor® 710 conjugated), CD226 (eBioscience clone TX25, FITC conjugated), and PD-1 (BD Biosciences clone EH12.1, Alexa Fluor® 647 conjugated). Cell viability was assessed using Live/Dead Cell Viability Assays (Life Technologies). Samples were run on a BD LSRFortessa or BD FACSAria II, as previously described. FlowJo software (Tree Star Inc.) was used for analysis after gating on live cells, with doublet exclusion followed by gating on CD4 and CD8 T cells.

In vitro proliferation assay with TIGIT blockade
Peripheral blood from patients with glioblastoma was obtained on the day of surgery, and mononuclear cells were isolated from whole blood by Ficoll-Paque gradient centrifugation and cryopreserved in GemCell human AB serum (GemBio) with 10% DMSO in liquid nitrogen. After thawing, cells were stained with LIVE/DEAD™ Fixable Dead Cell Stain kit (Invitrogen), αCD4 (clone RPA-T4), αCD8 (clone RPA-T8), αCD25 (clone 2A3), and αCD127 (clone hIL-7R-M21, all from BD Biosciences), and CD4 and CD8 T cells were sorted on a BD FACSAria™ III machine. Tregs (defined as the top 2%–4% CD4+CD25hiCD127lo) were removed from the CD4 gate.

After sorting, cells were stained with CellTrace™ Violet and seeded over round bottom 96-well plates that had been coated with CD3 2 μg/mL (clone UCHT1, BD Biosciences) at 20,000 T cells/well in 200 μL of RPMI 1640 media (Gibco) supplemented with 2 nM 1-glutamine, 5 mM HEPES, 100 U/μL penicillin/streptomycin (Biowhittaker), 0.5 mM sodium pyruvate, 0.05 mM nonessential amino acids (Life Technologies; complete RPMI), and 5% GemCell human AB serum (GemBio) with soluble agonistic αCD28 antibody (clone 28.2, BD Biosciences) at 1 μg/mL, and blocking αTIGIT antibody (clone 3F9, a kind gift of Pr. Vijay K. Kuchroo) at 20 μg/mL or isotype control (mouse IgG1 kappa, clone P3.6.2.8.1 from eBioscience) at 20 μg/mL. After 5 days, cells were stained with LIVE/DEAD™ Fixable Dead Cell Stain kit (Invitrogen), αTIGIT (clone MBSA43 from eBioscience) and αCD226 (clone DX11 from eBioscience). Stained Tregs were washed and acquired on a BD Fortessa™ flow cytometer.

Statistics and data availability
Statistical analysis was performed in GraphPad Prism. When comparing 2 conditions within the same individual, we used paired 2-tailed t tests. For comparisons across 2 groups of unrelated individuals, we used unpaired 2-tailed t tests. p Values <0.05 were considered significant. All anonymized data will be shared by request with any qualified investigator.

Results
We examined the expression of TIGIT, CD226, CD155, PD-1, and PD-L1 in tumor-infiltrating T cells in glioblastoma and demyelinating lesions from patients with MS by immunohistochemistry. The percentage of TIGIT+ T cells was substantially higher in GBM infiltrates compared with MS lesions (figure 1, A and C). Similarly, the percentage of CD226+ lymphocytes was higher in glioblastoma than in MS, although cellular expression was overall low and had a punctate appearance. CD155, the ligand for TIGIT and CD226, was present at a low level in infiltrating lymphocytes in glioblastoma and MS, but was highly expressed by GBM tumor cells, perivascular monocytes and, to a lower degree, by cortical neurons (figure 1B). Finally, the percentage of infiltrating lymphocytes that expressed PD-1 and PD-L1 was similar in GBM and MS (figure 2, A and B). In addition, we compared the percentage of TIGIT+ and CD226-expressing lymphocytes in perivascular cuffs and in the lesion parenchyma. In GBM, we found that the percentage of TIGIT+ T cells was significantly higher in tumor tissue than in perivascular infiltrates. Furthermore, we observed a gradient in the opposite direction for CD226+ lymphocytes, with higher frequencies in perivascular cuffs compared with tumor parenchyma. In MS lesions, the prevalence of TIGIT+ and CD226+ lymphocytes did not differ significantly between perivascular and parenchymal infiltrates (figure 2C).

We used freshly resected (unfixed) tumor tissue from newly diagnosed patients with glioblastoma to examine expression of TIGIT and CD226 by tumor-infiltrating T cells with flow cytometry. We observed that the majority of CD8 but not CD4 T cells were TIGIT positive, whereas CD226 was expressed at higher rates by CD4 T cells compared with CD8 (figure 3, A and B). Moreover, because TIGIT and CD226
have been reported to interact in cis, i.e., on the same cell, we assessed coexpression of the 2 molecules by flow cytometry and found that the majority of tumor-infiltrating CD8 T cells expressing CD226 were also positive for TIGIT (figure 3C).

We then compared TIGIT/CD226 expression in tumor-infiltrating and blood-derived lymphocytes of patients with glioblastoma and healthy controls. The frequency of TIGIT$^+$ CD8 but not CD4 T cells was increased in tumor tissue compared with peripheral blood of patients with glioblastoma, whereas CD226$^+$ CD8 lymphocytes were significantly reduced in the tumor compared with blood, where they coexpressed similar levels of TIGIT (figure 3D). Moreover, comparing the frequency of circulating TIGIT$^+$ and CD226$^+$ T cells between patients with glioblastoma and healthy controls highlighted a peripheral signature of the disease. Overall, patients with glioblastoma showed strong enrichment of TIGIT but not PD-1 expressing CD4 and CD8 T cells compared with healthy controls (figure 4). Although the frequency of CD226$^+$ CD4 and CD8 T cells was not significantly different between patients and controls (figure 4C), CD226$^+$ T cells from patients with glioblastoma coexpressed higher levels...
of TIGIT compared with healthy controls (figure 4, C and D).

Finally, we asked whether the enlarged TIGIT⁺ compartment in the circulation of patients with glioblastoma could be functionally modulated by TIGIT blockade. For this, we sorted CD4 T effectors (after removal of the CD25highCD127low Treg population) and CD8 T cells from the peripheral blood of 6 additional patients with glioblastoma and measured proliferation in response to αCD3/αCD28 stimulation in the presence of an αTIGIT blocking antibody or isotype control. When gating on TIGIT⁺ cells after 4 days of stimulation, we observed that TIGIT blockade conferred a significant increase in proliferation, which was more pronounced in CD4 than CD8 T cells and in cultures with low proliferation at baseline. Moreover, blocking TIGIT also induced heightened expression of CD226 on TIGIT⁺ cells (figure 5, A and B).

Discussion

Immune checkpoint receptors are a family of coinhibitory receptors that modulate T-cell activation. The interactions between coinhibitory receptors on tumor-infiltrating T cells and their ligands expressed by tumor cells are believed to contribute to the failure of the immune system to reject tumors. Although therapeutic blockade of this interaction has yielded dramatic results in the therapy of multiple cancer types, therapeutic trials with the immune checkpoint inhibitors anti-PD-1 and CTLA-4 in patients with glioblastoma have not been successful. This suggests that PD-1 signaling might be redundant in the tumor microenvironment of glioblastoma, where additional coinhibitory pathways may be operative. To identify coinhibitory pathways that are important in the brain, we hypothesized that comparison of T cells in lesions from patients with MS with TILs from patients with...
glioblastoma may reveal novel targets for immunotherapy of brain tumors.

Previous studies have reported frequencies of TIGIT+ tumor-infiltrating lymphocytes in glioblastoma (25%–60%), similar to the ones observed by us, although these studies have not addressed whether TIGIT expression on T cells occurs in any CNS environment or is a feature specific to the glioblastoma infiltrate.20,26 Here, we report that TIGIT-expressing lymphocytes were substantially higher in glioblastoma infiltrates than in MS lesions, where TIGIT expression was essentially absent. Given the abundant expression of the TIGIT ligand, CD155, on glioblastoma cells, this suggests that TIGIT signaling critically limits antitumor responses in GBM. In contrast, the relative absence of TIGIT/CD155 in normal white matter and MS lesions indicates that TIGIT signaling does not occur constitutively in the CNS. Moreover, PD-1/PD-L1+ lymphocytes were present in both conditions, indicating that PD-1 signaling is not a distinguishing feature between inflammatory responses in GBM and MS.

Although we observed a greater percentage of CD226-expressing lymphocytes in tumor infiltrates compared with MS lesions, its coexpression with TIGIT is likely to disrupt CD226 homodimerization15 and thereby renders CD226 nonfunctional. In contrast, the nearly absent expression rate of TIGIT in infiltrating lymphocytes in MS lesions suggests low TIGIT/CD226 coexpression, resulting in undisrupted CD226 function.
The increased percentage of TIGIT+ lymphocytes in tumor parenchyma compared with perivascular infiltrates, the high expression CD155 in glioblastoma cells, and the relative decrease of CD226+ T cells within the tumor tissue all suggest that CD155-induced TIGIT signaling is most pronounced in direct proximity to tumor tissue. Further investigations will elucidate whether the tumor microenvironment locally induces upregulation of TIGIT and downregulation of CD226 or preferentially attracts and retains TIGIT+CD226− lymphocytes.

Finally, TIGIT expression was increased in peripheral T cells in patients with glioblastoma compared with healthy controls, whereas expression of CD226 was decreased. This novel observation could indicate a systemic leakage of TIGIT-inducing factor and/or recirculation of TIGIT+ T cells between the periphery and the tumor bed. Trafficking of T cells between tumor and periphery would present an opportunity to gain insight into induction of TIGIT expression, to monitor the state of tumor-infiltrating lymphocytes, and to block TIGIT activity peripherally, thereby circumventing the obstacle of the blood-brain barrier for therapeutic antibodies. Indeed, circulating TIGIT+ T cells from patients with GBM stimulated in vitro in the presence of a blocking αTIGIT antibody displayed increased proliferation and expression of...
CD226, an effect that was more pronounced in CD4 than CD8 T cells. The elevated expression of TIGIT but only moderate response to TIGIT blockade of circulating CD8 T cells could indicate that these cells represent a terminally differentiated subpopulation with limited self-renewal and reinvigoration properties. Moreover, although cytotoxic CD8 T cells can directly kill tumor cells, mechanisms other than intrinsic coinhibitory receptor signaling can control their cytotoxic functions. Indeed, recent studies in melanoma models have shown that CD4 T cell help is needed for CD8 T cells to acquire cytotoxic functions that mediate tumor rejection and that the effect of TIGIT blockade in vivo was mediated predominantly by CD4+ Tregs but resulted in increased proinflammatory activity of CD8 T cells.

Finally, TIGIT blockade increased the expression of CD226 on TIGIT+ CD4 and, to a lesser extent, on CD8 T cells, suggesting that, in addition to increased proliferation, these T cells acquire a potential for stronger co-stimulation.

In summary, our study provides evidence for a critical role for the CD155/TIGIT axis on T cells in immune evasion of glioblastoma. Further work is warranted to elucidate the role of these molecules on the function of other immune cell populations capable of tumor rejection, such as NK cells. Together with existing studies, our results contribute a mechanistic rationale for the development of immunotherapy that targets TIGIT signaling in GBM, either alone or in combination with anti PD-1 or anti-CTLA-4 checkpoint inhibition.

Limitations of our study include that we did not explore expression of CD112, a low-affinity ligand for TIGIT and CD226. Further work exploring the pattern of expression of CD112 might help quantify the overall level of engagement that each receptor receives in the tumor microenvironment. Moreover, our staining experiments have been performed with brightfield single-antibody labeling rather than fluorescent double labeling, which allows only an estimate of the percentage of checkpoint receptor/ligand

Figure 5 TIGIT blockade increases proliferation and CD226 expression on TIGIT+ CD4 and CD8 T cells from patients with GBM
expressing lymphocytes but permits a better assessment of cells within the lesion environment.

Acknowledgment

The authors thank the operating room staff at Yale-New Haven Hospital and Jonathan Cruz for assistance in obtaining patient samples.

Study funding

This was funded by the National Multiple Sclerosis Society (RG 4866-A-2), the Gregory M. Kiez and Mehmet Kutman Foundation, and NIH Grants P01 AI045575 (DP) and NIH U19 AI089992, P01 AI073748, U24AI11867, R0AI22220, UM1HG009390, P01 AI039671, P50CA121974, the Nancy Taylor Foundation for Chronic Diseases, and NMSS grants RG-1802-30153CA and 1061-A-18 (DAH).

Disclosure

Dr. Hafler has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, and Genentech. In the past 10 years, he has been a consultant for Bayer Pharmaceuticals, Biohaven Pharmaceutical, Bristol-Myers Squibb, Compass Therapeutics, Eisai Pharmaceuticals, EMD Serono, Genentech, Juno Therapeutics, McKinsey&Co., MedImmune/AstraZeneca, Mylan Pharmaceuticals, NeuroPhage Pharmaceuticals, NKT Therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Questcor Pharmaceuticals, Roche, Sage Therapeutics, Sanofi Genzyme, Toray Industries, and Versant Venture. Dr. Lucca, Dr. Lerner, Mr. Park, Ms. DeBartolo, Mr. Harnett, Dr. Kumar, Dr. Ponath, Dr. Raddassi, Dr. Huttner, and Dr. Pitt report no disclosures. Go to Neurology.org/NN for full disclosures.

Publication history

Received by Neurology: Neuroimmunology & Neuroinflammation April 1, 2019. Accepted in final form February 7, 2020.

Appendix

### Authors

| Name                  | Location                  | Contribution                                  |
|-----------------------|----------------------------|-----------------------------------------------|
| Gerald Ponath, PhD    | Yale University, New Haven| Oversaw experimental performance and data analysis |
| Khadir Raddassi, PhD  | Yale University, New Haven| Coordinated clinical sample acquisition         |
| Anita Huttner, MD     | Yale University, New Haven| Oversaw evaluation of tumor tissue             |
| David A. Hafler, MD   | Yale University, New Haven| Designed and conceptualized the study         |
| David Pitt, MD        | Yale University, New Haven| Designed and conceptualized the study, interpreted the data, and wrote the manuscript |

### References

1. Kim TK, Herbst RS, Chen L. Defining and understanding adaptive resistance in cancer immunotherapy. Trends Immunol 2018;39:624–631.
2. Baumsteiner SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol 2016;34:539–573.
3. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.
4. Wolchok JD, Kogler H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369:122–133.
5. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–1833.
6. Celli D, Grünwald V, Escudier B, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol 2019;20:297–310.
7. Overman MJ, Loniardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018;36:773–779.
8. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:1283–1294.
9. Hughes J, Vadattu N, Snod M, et al. Precipitation of autoimmunity diabetes with anti-PD-1 immunotherapy. Diabetes Care 2015;38:e55–e57.
10. Cao Y, Nylander A, Ramanan S, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology 2016;86:1553–1556.
11. Kostine M, Cliche L, Lazaro E, et al. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): an emerging challenge. Rev Med Interne 2017;38:513–525.
12. Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009;10:48–57.
13. Boles KS, Vemuri W, Facchetti F, et al. A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol 2009;39:695–703.
14. Locascio D, Melone M, Reichert J, et al. TIGIT selectively inhibits proinflammatory Th1 and Th17 cell responses. J Immunol 2012;188:3869–3875.
15. Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates T cell effector function. Cancer Cell 2014;26:923–937.
16. Joller N, Locazzo E, Burket PR, et al. Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity 2014;40:569–581.
17. Lucca LE, Axta PP, Singer ER, Nolan NM, Domingo-Villar M, Hafler DA. TIGIT signaling regulates suppressor function of Th1 Tregs. JCI Insight 2019;4:124427.
18. Chauvin JM, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8+ T cells in melanoma patients. J Clin Invest 2015;125:2046–2058.
19. Dixon KO, Schorr M, Nevin J, et al. Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity. J Immunol 2018;200:3000–3007.
20. Hung AL, Maxwell R, Theodros D, et al. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM. Oncoimmunology 2018;7:e146679.
21. Tabata H, Hara M, Kitani A, et al. Expression of TLIiS1 on T cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 1989;52:366–375.

22. Hafler JP, Maier LM, Cooper JD, et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun 2009;10:5–10.

23. Joller N, Hafler JP, Brynedal B, et al. Cutting edge: TIGIT has T cell-intrinsic inhibitory functions. J Immunol 2011;186:1338–1342.

24. Dardalhon V, Schubart AS, Reddy J, et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol 2005;175:1558–1565.

25. Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol 2018;20:674–686.

26. Woroniecka K, Chongsathidkiet P, Rhodin K, et al. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin Cancer Res 2018;24:4175–4186.

27. Zander R, Schauder D, Xin G, et al. CD4+ T cell help is required for the formation of a cytolytic CD8+ T cell subset that protects against chronic infection and cancer. Immunity 2019;51:1028–1042.e4.

28. Kurtulus S, Sakuishi K, Ngiow SF, et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest 2015;125:4053–4062.
Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS
Liliana E. Lucca, Benjamin A. Lerner, Calvin Park, et al.
Neurol Neuroimmunol Neuroinflamm 2020;7;
DOI 10.1212/NXI.0000000000000712

This information is current as of April 8, 2020

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/7/3/e712.full.html

References
This article cites 28 articles, 6 of which you can access for free at:
http://nn.neurology.org/content/7/3/e712.full.html#ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Autoimmune diseases
http://nn.neurology.org/cgi/collection/autoimmune_diseases
Multiple sclerosis
http://nn.neurology.org/cgi/collection/multiple_sclerosis
Primary brain tumor
http://nn.neurology.org/cgi/collection/primary_brain_tumor

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2332-7812.